ArticleInternational medical case reports journal2026
Case Report: Liver Metastasis from Ductal Carcinoma In Situ of the Breast.
Article in International medical case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This article reports a rare case of liver metastasis in a patient with breast ductal carcinoma in situ (DCIS) after surgery, aiming to emphasize the rarity and potential metastatic risk of DCIS, especially liver metastasis, and provide reference for clinical diagnosis and treatment. Patients and Methods: The clinical data of a 35-year-old female patient with liver metastasis from DCIS admitted to our hospital were collected, and the latest literature and clinical guidelines were systematically reviewed. Results: The patient was diagnosed with high-grade, HER2-positive, large-volume (5.0 cm × 3.5 cm) DCIS (TisN0M0) in September 2021. Liver metastasis was confirmed 5 months after surgery. After 10 cycles of TCbHP regimen (docetaxel + carboplatin + trastuzumab + pertuzumab), liver metastases achieved complete remission. Subsequent maintenance therapy with HP combined with capecitabine maintained stable disease without recurrence. Conclusion: Distant metastasis of DCIS is extremely rare but can occur in high-risk populations. High-grade, large tumor size (>3 cm), HER2 positivity, and high Ki-67 are independent high-risk factors with moderate-to-high evidence levels. Early identification of high-risk DCIS and active anti-HER2 targeted combination therapy can significantly improve the prognosis of metastatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.